Team Details

Contraline
University of Virginia
Of the 1.5 billion sexually active men worldwide, 73% rely on their female partners to use contraception. Currently, only two options exist for men: condoms and vasectomy. Condoms are single-use, have a failure rate of 18%, and dissatisfaction rate of 57%. Vasectomy is a surgical procedure that is permanent and can have complications including chronic pain. Contraline is developing a novel male contraceptive that is long-lasting, non-hormonal, and reversible. It comes in the form of an echogenic (ultrasound-visible) polymer gel that is implanted into the vas deferens. The gel blocks sperm, while allowing fluids to travel through. This is the first contraceptive that can be inserted, imaged, and reversed completely non-surgically using a standard ultrasound. Contraline is inventing the future of male contraception.
Melissa Skoff
Biomedical Engineering
Andrew Portell
Biomedical Engineering
Christopher Winans
Biomedical Engineering
Brittainy Hereford
Biomedical Engineering
Kevin Eisenfrats
Biomedical Engineering